Who is sponsoring NCT04258644?

NCT04258644 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT04258644?

Interventions in NCT04258644: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1.

What condition does NCT04258644 study?

NCT04258644 studies Gastric Cancer.

Is NCT04258644 still recruiting?

NCT04258644 is currently status unknown. Last updated 6 February 2020.

Last reviewed 2020-02-06 · How we verify

NCT04258644

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Status unknown Phase 2 Last updated 6 February 2020

What this trial tests

Phase 2 trial testing Camrelizumab+Apatinib+Paclitaxel-albumin+S-1 in Gastric Cancer in 30 participants. Status unknown.

Timeline

1 March 2020

Primary endpoint
28 February 2023

28 February 2023

Quick facts

Lead sponsor	Beijing Friendship Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 March 2020
Primary completion	28 February 2023
Estimated completion	28 February 2023
Sites	1 location across China

Drugs / interventions tested

Camrelizumab+Apatinib+Paclitaxel-albumin+S-1 — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Beijing Friendship Hospital

Who can join

Adults 18 to 70, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of gastric cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David E, Perez C, Rodallec A. · · 2022 · cited 2× · PMID 36365144 · DOI 10.3390/pharmaceutics14112326

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04258644 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 6 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04258644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing